Application of ellagic acid in preparing drugs for reducing polymyxin cytotoxicity and / or neurotoxicity and nephrotoxicity, pharmaceutical composition and application
Through the composition of ellagic acid and polymyxin, the cytotoxicity and organ toxicity of polymyxin in clinical applications have been solved, which significantly reduces its toxic side effects, improves the treatment index, and improves renal function and nerves. Tissue injury.
Patent Information
- Application Number
- CN202410571407.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-05-09
AI Technical Summary
In clinical applications, polymyxins have major cytotoxic and organ toxic side effects, including nephrotoxicity and neurotoxicity, as well as narrow treatment windows and drug resistance transmission.
Using a composition of ellagic acid and polymyxin, the cytotoxicity and nephrotoxicity of polymyxin are reduced by adjusting its molar ratio and dosage form, significantly increasing cell viability, and demonstrating its onset of kidneys and neural tissues through animal models. Protective effect.
It significantly inhibits the cytotoxicity, neurotoxicity and nephrotoxicity of polymyxin, improves the clinical treatment index, reduces the toxicity side effects of polymyxin, and improves renal function and nerve tissue damage.
Smart Images

Figure CN118340768B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to the use of ellagic acid in the preparation of drugs for reducing polymyxin cytotoxicity and / or neurotoxicity and nephrotoxicity, a pharmaceutical composition and the use thereof. Background Art
[0002] Polymyxin (also known as polymyxin) is an antibacterial polypeptide found in the culture fluid of Bacillus polymyxa. There are five types: A, B, C, D, and E. The antibacterial spectrum is similar to each other and has a wide range, especially against Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Polymyxin E (also known as polymyxin E, colistin, Polymyxin E), CAS number: 1066-17-7, English name: Colistin, trade name anti-enemycin, colistin, colistin. Clinical application is mainly in the form of sulfate or mesylate, that is, polymyxin E sulfate and mesylate.
[0003] However, the current clinical polymyxin injection has a large toxic effect. The toxic side effects of polymyxin are mainly manifested in: (1) nephrotoxicity. Nephrotoxicity is a relatively common and serious side effect. It may cause the patient's renal function to decline. Proteinuria, tubular urine, azotemia and increased creatinine levels may occur. This is its main damage to renal function; (2) neurotoxicity. During the use of polymyxin, the patient may experience dizziness, ataxia, drowsiness, and peripheral paresthesia. These are all side effects of the nervous system caused by polymyxin. Nephrotoxicity and neurotoxicity are the most common toxic side effects of polymyxin E in clinical application. Among them, clinical nephrotoxicity occurs in up to 60%, neurotoxicity occurs in about 7%, and mild peripheral neurotoxicity symptoms are more obvious, with an incidence of up to 100%. In addition, polymyxin also has clinical application problems such as a narrow therapeutic window and the spread of drug resistance.
[0004] In order to improve the therapeutic efficacy of polymyxin and reduce its cytotoxic effects, there is an urgent need in the art to provide agents that reduce the cytotoxicity, neurotoxicity and nephrotoxicity of polymyxin. Summary of the invention
[0005] The purpose of the present invention is to provide the use of ellagic acid in the preparation of drugs for reducing polymyxin cytotoxicity and / or neurotoxicity and nephrotoxicity, a pharmaceutical composition and use thereof, so as to solve the problems of cytotoxicity and organ toxicity generated during polymyxin treatment.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides application of ellagic acid in preparing a drug for reducing polymyxin cytotoxicity and / or neurotoxicity and nephrotoxicity.
[0008] Preferably, the polymyxin is polymyxin E or polymyxin B.
[0009] The invention provides a pharmaceutical composition for reducing the toxicity of polymyxin, comprising ellagic acid and polymyxin.
[0010] Preferably, the molar ratio of ellagic acid to polymyxin is (10-20):400.
[0011] Preferably, the polymyxin is polymyxin E sulfate.
[0012] Preferably, the pharmaceutical composition is in the form of tablets, capsules, sustained-release tablets, controlled-release tablets, oral liquid, syrup, injection liquid, pills or lyophilized powder injection.
[0013] The present invention provides the use of the pharmaceutical composition for reducing the toxicity of polymyxins described in the above technical solution in the preparation of drugs for reducing the cytotoxicity and / or neurotoxicity and nephrotoxicity of polymyxins.
[0014] The present invention provides the use of ellagic acid, a natural active small molecule substance, in the preparation of drugs that reduce the cytotoxicity of polymyxins and / or neurotoxicity and nephrotoxicity. The present invention uses ellagic acid in combination with polymyxin, and compared with the polymyxin alone treatment group, the cell viability shows a certain degree of increase; specifically, when the final use concentration of ellagic acid is 20 μM, when used in combination with polymyxin E, the cell viability of PC12 cells and HT22 cells is significantly increased to 76.1% and 78.7%, which is significantly different from the control. Therefore, the present invention uses ellagic acid in combination with polymyxin E to treat, which can significantly inhibit the cytotoxic effect of polymyxin E.
[0015] The present invention proves by establishing a renal injury model of mice caused by polymyxin E, and ellagic acid combined with polymyxin E treatment can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone to mice, which is specifically manifested in the improvement of the histopathology of brain tissue and kidney tissue, which is specifically embodied in the significant increase in serum urea nitrogen and creatinine levels, while causing obvious tubular necrosis, epithelial cell shedding and the appearance of cast structures. After ellagic acid combined treatment, serum urea nitrogen and creatinine levels are significantly reduced, and renal tubular pathological changes are significantly improved, indicating that ellagic acid combined with polymyxin E treatment can significantly reduce the nephrotoxicity caused by polymyxin E. At the same time, after colistin injection treatment, obvious nerve cell damage can be induced, and ellagic acid supplementation can significantly reduce colistin-induced nerve tissue damage. Therefore, the present invention adopts ellagic acid combined with polymyxin E, which can significantly inhibit the cytotoxicity, neurotoxicity and nephrotoxicity of polymyxin E.
[0016] The present invention provides a solution to the problem of large toxic and side effects of polymyxin in clinical application, can provide a basis for clinical drug combination, reduce the clinical toxic and side effects of polymyxin, thereby improving clinical output and therapeutic index, and can solve the problem of low clinical therapeutic index of polymyxin. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The results show the protective effect of ellagic acid on the cytotoxicity of PC12 and HT22 cells induced by polymyxin E; A represents PC12 cells; B represents HT22 cells; compared with the control group, ** represents an extremely significant difference; compared with the group treated with polymyxin E alone, ## represents an extremely significant difference;
[0018] Figure 2 The results of serum urea nitrogen test of mice in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group;
[0019] Figure 3 The results of serum creatinine test of mice in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group;
[0020] Figure 4 The kidney tissue pathological sections and semi-quantitative scoring results of the mice in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group were shown;
[0021] Figure 5 Pathological sections of mouse brain tissue and semi-quantitative scoring results of tissue damage in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group. DETAILED DESCRIPTION
[0022] The present invention provides application of ellagic acid in preparing a drug for reducing polymyxin cytotoxicity and / or neurotoxicity and nephrotoxicity.
[0023] In the present invention, the ellagic acid is used to prepare a drug for reducing the cytotoxicity of polymyxin, or is used to prepare a drug for reducing the neurotoxicity and nephrotoxicity of polymyxin; or is used to prepare a drug for reducing the cytotoxicity of polymyxin and a drug for reducing the neurotoxicity and nephrotoxicity of polymyxin at the same time.
[0024] The present invention has no particular limitation on the source of the ellagic acid, and any commercially available product known in the art may be used.
[0025] In the present invention, the polymyxin is preferably polymyxin E or polymyxin B.
[0026] The invention provides a pharmaceutical composition for reducing the toxicity of polymyxin, comprising ellagic acid and polymyxin.
[0027] In the present invention, the molar ratio of ellagic acid to polymyxin is preferably (10-20):400, more preferably 20:400.
[0028] In the present invention, the polymyxin is preferably polymyxin E sulfate.
[0029] In the present invention, the dosage form of the pharmaceutical composition is preferably tablets, capsules, sustained-release tablets, controlled-release tablets, oral liquids, syrups, injection liquids, dripping pills or freeze-dried powder injections. The present invention has no particular limitation on the preparation methods of different dosage forms, and the corresponding dosage forms can be obtained by methods well known in the art to meet the above dosage requirements.
[0030] The present invention provides the use of the pharmaceutical composition for reducing the toxicity of polymyxins described in the above technical solution in the preparation of drugs for reducing the cytotoxicity and / or neurotoxicity and nephrotoxicity of polymyxins.
[0031] When the pharmaceutical composition is used to prepare a drug for reducing the cytotoxicity of polymyxins and / or neurotoxicity and nephrotoxicity, the present invention has no special limitation on the concentrations of polymyxin and ellagic acid in the pharmaceutical composition, which can be adjusted according to actual needs; in the experimental model of the present invention, when the pharmaceutical composition is used to prepare a drug for reducing the cytotoxicity of polymyxins, the effective concentration of polymyxin E sulfate is preferably 400 μM, and the effective concentration of ellagic acid is preferably 10-20 μM, more preferably 20 μM; the effective concentration is the concentration used to exert the effect.
[0032] In the experimental model of the present invention, when the pharmaceutical composition is used to prepare a drug for reducing polymyxin neurotoxicity and nephrotoxicity, the dosage of ellagic acid is preferably 20-100 mg / kg body weight per day, and the dosage of polymyxin sulfate is preferably 20 mg / kg body weight per day.
[0033] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0034] Drugs used in the examples of the present invention: Ellagic acid was purchased from Shanghai Aladdin Company with a purity of ≥96%. Colistin sulfate was purchased from Hebei Shengxue Dacheng Tangshan Pharmaceutical Company with a potency of ≥23000 U / mg of colistin.
[0035] A certain amount of polymyxin sulfate was weighed to prepare a polymyxin sulfate stock solution with a concentration of 16 mg / mL.
[0036] Ellagic acid was prepared with DMSO to prepare an ellagic acid stock solution with a stock concentration of 3 mg / mL.
[0037] All prepared stock solutions were stored in a -20°C refrigerator.
[0038] Example 1
[0039] Protective effect of ellagic acid on cytotoxicity of polymyxin
[0040] 1.1 Test cell lines
[0041] Rat PC12 neuronal cell line and mouse hippocampal neuronal cells (HT22) were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences and preserved by the National Veterinary Drug Safety Evaluation Center of China Agricultural University.
[0042] 1.2 Cell viability assay
[0043] Ellagic acid pretreatment: PC12 cells were cultured at 8×10 3 Each well of the 96-well plate was inoculated with 100 μL of culture medium, and the original culture medium was discarded when the cell density reached 50%. After adding 100 μL of culture medium to each well of the 96-well plate, an appropriate volume of ellagic acid stock solution was added to make the final concentration of ellagic acid 5, 10 and 20 μM, and PC12 cells were pretreated for 2 h. Then, an appropriate amount of polymyxin E sulfate stock solution was added to make the final concentration of polymyxin E sulfate 400 μM, and the corresponding solvent control group (i.e., containing 0.2wt% DMSO), ellagic acid single drug group (i.e., the corresponding ellagic acid final concentration was 20 μM), colistin single drug group and ellagic acid pretreatment group were set up and cultured for 24 hours.
[0044] According to the above-mentioned treatment steps of PC12 cells with ellagic acid, HT22 cells were pretreated with ellagic acid. The final concentrations of ellagic acid for HT22 cells were 5, 10 and 20 μM. After 2 h of pretreatment, the polymyxin sulfate mother solution was added to make the final concentration of polymyxin sulfate 400 μM, and the corresponding solvent control group (i.e., containing 0.2wt% DMSO), ellagic acid single drug group (i.e., the corresponding ellagic acid final concentration was 20 μM), colistin single drug group and ellagic acid pretreatment group were set up and cultured for 24 hours.
[0045] After drug treatment, the culture medium was discarded, and 100 μL of CCK-8 working solution was added to each group of cells in the dark, and then transferred to a 37 °C cell culture incubator for incubation for 1 h. After the end, the OD value was measured at a wavelength of 450 nm.
[0046] Cell survival rate (cell viability) = [(As-Ab) / (Ac-Ab)] × 100%; As is the OD value of the drug treatment group; Ab is the OD value of the background blank control group; Ac is the OD value of the control group. Each treatment group was subjected to at least three independent experiments.
[0047] 1.3 Test results
[0048] The results of ellagic acid treatment reducing the cytotoxicity of polymyxin E to PC12 and HT22 cells are shown in Figure 1 , where A represents PC12 cells; B represents HT22 cells; compared with the control group, ** represents extremely significant difference; compared with the polymyxin E alone-treated group, ## represents extremely significant difference; where “-” represents no treatment, and “+” represents corresponding drug treatment;
[0049] The results of cell viability test were obtained by treating cells with ellagic acid or polymyxin E alone or in combination. The specific results are analyzed as follows:
[0050] Compared with the control group, there was no significant difference in cell viability after ellagic acid was treated with 10 μM and 20 μM alone; in PC12 cells, compared with the control group, after polymyxin E was treated with 400 μM for 24 h, the viability of PC12 cells decreased to 48.5%, with a very significant difference (**). Compared with the group treated with polymyxin alone, the cell viability showed a certain degree of improvement after ellagic acid combined with polymyxin E treatment, in which ellagic acid at 10 μM combined with polymyxin E treatment increased the cell viability to 69.3%, with a very significant difference (##); ellagic acid at 20 μM combined with polymyxin E treatment, the cell viability increased to 76.1%, with a very significant difference (##). In HT22 cells, compared with the control group, after treatment with 400 μM polymyxin E for 24 h, the viability of HT22 cells decreased to 44.0%, with an extremely significant difference (**); compared with the group treated with polymyxin alone, the cell viability showed a certain degree of improvement after treatment with ellagic acid combined with polymyxin E, in which the cell viability increased to 66.7% when ellagic acid was combined with polymyxin E at 10 μM, with an extremely significant difference (**); the cell viability increased to 78.7% when ellagic acid was combined with polymyxin E at 20 μM, with an extremely significant difference (**); these data all indicate that ellagic acid combined with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E.
[0051] Example 2
[0052] Protective effect of ellagic acid supplementation on neuronal and renal damage induced by polymyxin in mice
[0053] 1 Materials
[0054] 1.1 Experimental animals
[0055] C57BL / 6, female, 8 weeks old, weight 18-22 g, purchased from Beijing Sibeifu Technology Co., Ltd.
[0056] 2 Test methods
[0057] 2.1 Animal husbandry and treatment
[0058] Mice were housed at the National Veterinary Drug Safety Evaluation Center, College of Veterinary Medicine, China Agricultural University, and fed with conventional pelleted feed with free access to water. The temperature was controlled at (22±2)°C and the humidity was (50±10)%. They were adaptively housed for 1 week before the experiment.
[0059] The 40 animals were randomly divided into 5 groups, 8 in each group, as follows:
[0060] Control group: mice were intraperitoneally injected with the same volume of normal saline as the experimental group, and orally administered with the same dose of 0.5wt% sodium carboxymethyl cellulose aqueous solution.
[0061] Polymyxin E model group: mice were intraperitoneally injected with polymyxin E, so that the single injection dose was 10 mg / kg body weight, twice a day, with an interval of 8 hours between each injection; that is, mice were given 20 mg / kg body weight of polymyxin E per day.
[0062] Ellagic acid control group: An appropriate amount of ellagic acid was mixed with a 0.5wt% sodium carboxymethyl cellulose aqueous solution to prepare a suspension containing ellagic acid at a concentration of 1 mg / mL, and the suspension was orally administered to mice at a concentration of 100 mg / kg body weight for 7 consecutive days; that is, the mice were given 100 mg / kg body weight of ellagic acid every day.
[0063] Ellagic acid high-dose protection group: An appropriate amount of ellagic acid and a 0.5wt% sodium carboxymethyl cellulose aqueous solution were prepared into a suspension containing ellagic acid at a concentration of 1 mg / mL, and the suspension was orally administered to mice at a dose of 100 mg / kg body weight. At the same time, polymyxin E was injected, with a single injection dose of 10 mg / kg body weight. Polymyxin was injected twice, with an interval of 8 hours each time; that is, the mice were given 100 mg / kg body weight of ellagic acid and 20 mg / kg body weight of polymyxin E every day.
[0064] Ellagic acid low-dose protection group: An appropriate amount of ellagic acid was mixed with a 0.5wt% sodium carboxymethyl cellulose aqueous solution to prepare a suspension containing ellagic acid at a concentration of 0.2 mg / mL, which was orally administered to mice at a dose of 20 mg / kg body weight. At the same time, polymyxin E was injected, with a single injection dose of 10 mg / kg body weight. Polymyxin was injected twice, with an interval of 8 hours between each injection; that is, the mice were given 20 mg / kg body weight of ellagic acid and 20 mg / kg body weight of polymyxin E every day.
[0065] Among them, the method for establishing the polymyxin E nephrotoxicity mouse model was carried out according to the method described in the prior art (Dai C, Tang S, WangY, Velkov T, Xiao X. Baicalein acts as a nephroprotectant that amelioratescolistin-induced nephrotoxicity by activating the antioxidant defencemechanism of the kidneys and down-regulating the inflammatory response. JAntimicrob Chemother. 2017 Sep 1;72(9):2562-2569).
[0066] After 7 days of continuous injection, mice were euthanized by intraperitoneal injection of an overdose of sodium pentobarbital (80 mg / kg) 24 hours after the last administration, and blood and kidney tissues were quickly collected. Serum and tissues were processed as follows.
[0067] 2.2 Determination of biochemical indicators
[0068] The collected mouse blood samples were centrifuged at 3000 rpm for 10 min, and the supernatant was aspirated. The changes of serum urea nitrogen and serum creatinine were detected using an automatic biochemical detector.
[0069] 2.3 Pathological examination and semi-quantitative scoring of kidney and brain tissues
[0070] The separated fresh kidney and brain tissue were washed with physiological saline, sampled and fixed in 10% neutral formalin, and after 48 hours, they were rinsed with water, dehydrated, transparent, waxed, embedded, sliced and stained in sequence, and the pathological changes of kidney and brain tissue were observed and photographed under a microscope. HE staining: paraffin sections were taken out and placed in a 60 ℃ constant temperature oven for 30 min; then dewaxed and dehydrated with ethanol, and immersed in double distilled water; hematoxylin staining for 10 min, rinsed with tap water, differentiated with hydrochloric acid ethanol; rinsed with running water until the sections turned blue; 95% ethanol for 30 s, alcohol eosin staining for 30 s, 95% ethanol for 30 s, 100% ethanol for 30 s; xylene transparent, neutral gum sealing.
[0071] After HE staining, a semiquantitative scoring system (SQS) was used to evaluate renal tissue injury. The SQS score was based on our previous publication (Antimicrob Agents Chemother, 2014 Jul;58(7):4075-85.). The specific criteria are as follows: SQS = grade score × injury percentage score; grade 1 (1 point): mild renal tubular injury, i.e., tubular dilatation, protruding nuclei, and the presence of a small number of tubular casts; grade 2 (4 points): severe renal tubular injury, i.e., necrosis of tubular epithelial cells and the presence of a large number of tubular casts; grade 3 (10 points): acute necrosis or infarction of the renal cortex or medulla. The percentage score of kidney section injury was as follows: <1% = 0, 1% ~ <5% = 1, 5% ~ <10% = 2, 10% ~ <20% = 3, 20% ~ <30% = 4, 30% ~ <40% = 5, ≥40% = 6. Finally, the SQS evaluation results were as follows: SQS + 0 = no significant change (comprehensive score, <1); SQS + 1 = mild injury (comprehensive score, 1 ~ <15); SQS + 2 = mild to moderate injury (comprehensive score, 15 ~ <30); SQS + 3 = moderate injury (comprehensive score, 30 ~ <45); SQS + 1 = mild to moderate injury (comprehensive score, 45 ~ <60); SQS + 1 = severe injury (comprehensive score, ≥60).
[0072] Brain tissue pathology scoring was based on the existing technology (ACS Chem Neurosci. 2018 Apr 18;9(4):824-837), as follows: The scoring criteria were based on the following morphological changes: 0 (no change), 1 (mild change), 2 (dark staining or dense nuclei in neuronal cells), and 3 (significant neuronal cell loss).
[0073] 2.4 Statistical analysis
[0074] All results are expressed as mean ± SD. One-way ANOVA was performed using GraphPad 9.0 software, * indicates P < 0.05, ** indicates P < 0.01.
[0075] The results are as follows Figures 2~5 As shown:
[0076] Compared with the control group, daily injection of 20 mg / kg of polymyxin E for 7 consecutive days led to a significant increase in the levels of serum BUN and CRE in mice, and caused obvious pathological damage, including the shedding of renal tubular epithelial cells, necrosis and the formation of tubular structures. The average semi-quantitative pathological score increased to 2.5. Compared with the polymyxin E model group, oral administration of 20 mg / kg and 100 mg / kg of ellagic acid and combined treatment with 20 mg / kg of colistin significantly reduced serum urea nitrogen (the results of serum urea nitrogen detection of mice in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group are shown in Figure 2). Figure 2 The results of serum creatinine in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group were shown in Figure 3 shown) level.
[0077] The histopathological sections and semi-quantitative scores of tissue damage of mice in the control group, polymyxin E model group, ellagic acid control group, ellagic acid high-dose protection group and ellagic acid low-dose protection group of the present invention are as follows Figure 4 As shown in the figure, the corresponding pathological injury scores were reduced to 0.75 (P<0.01) and 0.5 (P<0.001), respectively. This indicates that ellagic acid combined with polymyxin E can significantly inhibit the nephrotoxicity of polymyxin E.
[0078] The pathological sections of the mouse brain tissues and the semi-quantitative evaluation diagram of tissue damage in the control group, the polymyxin E model group, the ellagic acid control group, the ellagic acid high-dose protection group and the ellagic acid low-dose protection group of the present invention are shown in FIG. Figure 5 As shown in the figure, compared with the control group, polymyxin E injected at 20 mg / kg per day for 7 consecutive days led to depression and significantly reduced activity. It could induce a certain degree of pathological changes in the neuronal tissue of the mouse brain. Some neurons showed certain abnormal changes, such as deepening of neuronal nuclear staining, and the brain tissue pathology score increased to 1.5 points. After ellagic acid supplementation, it could significantly improve the depression induced by polymyxin E. In the low-dose protection group and high-dose protection group of ellagic acid, the brain tissue pathology score decreased to 0.25 points and 0 points, respectively. This shows that ellagic acid combined with polymyxin E treatment can significantly inhibit the neurotoxicity of polymyxin E.
[0079] As can be seen from the above examples, the present invention uses ellagic acid in combination with polymyxin. Compared with the polymyxin alone treatment group, the cell viability after ellagic acid combined with polymyxin treatment shows a certain degree of increase. At a certain ellagic acid concentration, the viability of PC12 cells and HT22 cells is significantly increased. The combined cell viability of the two increases to 76.1 and 78.7%, respectively, which is significantly different from the control. It shows that when ellagic acid is combined with polymyxin E for treatment, the cytotoxic effect of polymyxin E can be significantly inhibited. Furthermore, by establishing a model of neural tissue and kidney damage in mice induced by polymyxin E, it was found that the renal function of mice was significantly reduced after polymyxin E treatment, which was specifically manifested by a significant increase in serum urea nitrogen and creatinine levels, and at the same time caused obvious tubular necrosis. After co-treatment with ellagic acid, serum urea nitrogen and creatinine levels were significantly reduced, and the pathological changes of renal tubules were significantly improved; this indicates that ellagic acid combined with polymyxin E treatment can significantly reduce the nephrotoxicity caused by polymyxin E; at the same time, after polymyxin E injection treatment, obvious nerve cell damage can be induced, and ellagic acid supplementation can significantly reduce polymyxin-induced neural tissue damage.
[0080] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of ellagic acid in the preparation of drugs for reducing the cytotoxicity and / or neurotoxicity and nephrotoxicity of polymyxin.
2. The use according to claim 1, It is characterized in that The polymyxin is polymyxin E or polymyxin B.
